MyFinsight
Home
Blog
About
Contact
Download
Download image
Total comprehensive
loss for the year, net...
-$74,770K
Unrealized gain on
available-for-sale securities, net...
$153K
Loss for the year
-$74,923K
Loss before tax
-$74,923K
Interest income
$6,473K
Supply revenue
$1,119K
Foreign exchange
gains/(losses)
-$82K
Fair value change -
warrants
$15,335K
Operating loss
-$65,980K
Revenue
$32K
Total operating
expenses
$66,012K
Selling, general and
administrative expenses
$27,418K
Research and development
expenses
$38,594K
Back
Back
Income Statement
source: myfinsight.com
NewAmsterdam Pharma Co N.V. (NAMS)
NewAmsterdam Pharma Co N.V. (NAMS)